Jongo Said Abdallah

In the News

Muhas don is new IHI board member

Prof. Kaaya. Ifakara Health Institute (IHI) Board of Governors (BOG) has appointed Prof. Sylvia Kaaya member of the IHI Board of Trustees (BOT) effective Wednesday January 10, 2018. The appointment …

Marcel steps down from IHI boards

Prof. Marcel Tanner has stepped down as Ifakara Health Institute (IHI) member of the Board of Trustees (BOT) and Board of Governors (BOG) effective Wednesday January 10, 2018. The Former …

Recent Projects

Development of a new tool for malaria mosquito surveillance to improve vector control

Malaria transmission is influenced not only by vector abundance, but as well by demographic traits such as vector species and age structure, as these influence the intensity by which the …

Demonstrating complete disruption of residual malaria transmission by eliminating Anopheles funestus mosquitoes from rural Tanzanian villages

In rural south-eastern Tanzania, where malaria prevalence has reduced by >60% since 2000, low-to-moderate transmission still persists despite very high coverage with long-lasting insecticidal bednets. Like in most residual transmission …

Jongo Said Abdallah

Research Scientist and Head of Clinical Trials Facility

Dr. Jongo Said Abdallah is a Physician specialized in Internal medicine and the head of theIHI  Clinical Trials Unit. As a senior research scientist his scientific knowledge and clinical expertise cut across the spectrum from the diagnosis, treatment and care to conducting advanced clinical research and managing clinical trials. He is leading a team of scientists and non-scientists in designing and conducting phase 1 to phase 3 Good Clinical Practice (GCP) compliant studies as well as analysis and reporting for regulatory review and licensure. His work is focused on conducting high quality clinical trials on the diseases of public health importance, mainly focusing on malaria and non-communicable diseases. His malaria research involvement include; the assessment of safety and efficacy of novel antimalarials  and transmission blocking potential as well as models for prevention; assessment of safety and efficacy for novel Good Manufacturing Practice (GMP) certified malaria vaccine candidates for malaria control and elimination; and mechanism for efficient  translation of research results into policy improvement and community well-being. He is an active member of the International Plasmodium falciparum Sporozoite Consortium (I-PfSPZ-C), and is actively involved in mapping out the clinical development pathway for the PfSPZ-based vaccines, in which thirty-seven research groups in 15 countries, are collaborating to advance candidate vaccines based on injectable Plasmodium falciparum (Pf) sporozoites (SPZ). He is currently, the principal investigator for the “Clinical Trial to Evaluate the Safety and Immunogenicity in Age De-Escalation of Direct Venous Inoculation of a Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults, Children, and Infants” in which the safety of the PfSPZ vaccine is being assessed for the first time in the world in pediatric population including infants from 6 months old and the efficacy for higher doses of PfSPZ vaccine is being assessed in African adult population.

View Dr. Jongo’s Research Interests & Publications


Evaluation of whole sporozoite vaccines for malaria elimination

Safety and immunogenicity of direct venus inoculation of Plasmodium falciparum sporozoite vaccine in adults, children and infants

Safety, immunogenicity and efficacy of intravenously administered attenuated Plasmodium falciparum sporozoite vaccine

© Ifakara Health Institute (IHI), 2016